News
10-05-2026, 08:10 PM
Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer.
More... (https://www.news-medical.net/news/20261005/Phase-III-trial-tests-MRD-guided-treatment-for-patients-with-ER-positiveHER2-negative-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20261005/Phase-III-trial-tests-MRD-guided-treatment-for-patients-with-ER-positiveHER2-negative-breast-cancer.aspx)